Quadramet & Velcade combo clinical trial

Cytogen Corporation (Nasdaq: CYTO) today announced the initiation of a multicenter Phase I clinical trial to investigate the use of QUADRAMET® (samarium Sm-153 lexidronam) in combination with bortezomib (Velcade®, Millennium Pharmaceuticals, Inc.) for the treatment of multiple myeloma. The clinical study will evaluate the safety profile and preliminary incidence and duration of clinical benefits of bortezomib in combination with QUADRAMET.

More Quadramet info can be found at
http://myelomic.blogspot.com/2005/11/quadramet-information.html